{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T13:20:03Z","timestamp":1753881603292,"version":"3.41.2"},"reference-count":27,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Microbiol Spectr"],"published-print":{"date-parts":[[2025,1,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:sec>\n            <jats:title\/>\n            <jats:p>\n              <jats:italic>Dermabacter hominis,<\/jats:italic>\n              a short gram-positive rod, is a part of the human skin flora, but can also cause infections (e.g., skin and soft tissue infections, bone and joint infections, abscesses, peritoneal dialysis-associated peritonitis, and bacteremia). Only limited data are available for antimicrobial resistance rates. Although CLSI does include coryneform genera in\n              <jats:italic>Corynebacterium<\/jats:italic>\n              spp. clinical breakpoints, they point out that only limited data are available on resistance rates. The aim of this study was to assess the minimal inhibitory concentration (MIC) of clinical isolates of\n              <jats:italic>D. hominis<\/jats:italic>\n              and to deduce breakpoints for disk diffusion.\n              <jats:italic>D. hominis<\/jats:italic>\n              (n = 30) from five laboratories in Germany were tested by broth microdilution and disk diffusion method. MICs were interpreted according to current clinical breakpoints for\n              <jats:italic>Corynebacterium<\/jats:italic>\n              spp. or pharmacokinetic\u2013pharmacodynamic breakpoints (EUCAST). To deduce breakpoints for disk diffusion, MICs were correlated with inhibition zone diameters. All isolates were susceptible to vancomycin, rifampicin, and linezolid (100%,\n              <jats:italic>n<\/jats:italic>\n              = 30\/30). Lower susceptibility rates were found for ampicillin (83%,\n              <jats:italic>n<\/jats:italic>\n              = 25\/30) followed by ceftriaxone (37%,\n              <jats:italic>n<\/jats:italic>\n              = 11\/30) and clindamycin (27%,\n              <jats:italic>n<\/jats:italic>\n              = 8\/30). All isolates were resistant to benzylpenicillin and daptomycin. Good correlations between disk diffusion and MIC (suggested breakpoints for susceptibility in brackets) were found for ampicillin (S \u2265 10 mm), ceftriaxone (S \u2265 24 mm), clindamycin (S \u2265 19 mm), levofloxacin (I \u2265 24 mm), linezolid (S \u2265 29 mm), rifampicin (S \u2265 38 mm), and vancomycin (S \u2265 21 mm). Due to limited variances in both MIC values and inhibition zone diameters, no disk diffusion breakpoint could be deduced for gentamicin and benzylpenicillin in our dataset.\n              <jats:italic>D. hominis<\/jats:italic>\n              has favorable susceptibility rates for vancomycin, rifampicin, and linezolid and shows correlations between MIC and disk diffusion diameter for selected antimicrobial agents. Thus, the development of clinical breakpoints for disk diffusion appears feasible.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>IMPORTANCE<\/jats:title>\n            <jats:p>\n              <jats:italic>Dermabacter hominis<\/jats:italic>\n              can cause infections in humans (e.g., skin and soft tissue infections, bone and joint infections, abscesses, peritoneal dialysis-associated peritonitis, and bacteremia). Currently, only limited data are available regarding the resistance rates of this specific pathogen. Data for the easy accessible disk diffusion method are missing. We were able to provide additional data on resistance rates of clinical\n              <jats:italic>D. hominis<\/jats:italic>\n              isolates to common antimicrobial agents and correlate these with disk diffusion diameters to derive breakpoints to further improve the antimicrobial susceptibility testing for this specific pathogen. In addition to that, we created a current overview of resistance rates from the existing literature. Our data provide deeper insight into resistance rates and antimicrobial susceptibility testing of this specific pathogen.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1128\/spectrum.01827-24","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T14:00:25Z","timestamp":1731679225000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":0,"title":["Antimicrobial susceptibility testing of\n            <i>Dermabacter hominis<\/i>"],"prefix":"10.1128","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1007-2621","authenticated-orcid":false,"given":"Tim","family":"Kintzinger","sequence":"first","affiliation":[{"name":"Institute of Medical Microbiology, University Hospital M\u00fcnster","place":["M\u00fcnster, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis","family":"Knaack","sequence":"additional","affiliation":[{"name":"Competence Center Microbiology and Hygiene, St. Franziskus Hospital M\u00fcnster","place":["M\u00fcnster, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00f6ren","family":"Schubert","sequence":"additional","affiliation":[{"name":"Max von Pettenkofer Institute, Ludwig-Maximilians-University M\u00fcnchen","place":["M\u00fcnchen, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Gro\u00df","sequence":"additional","affiliation":[{"name":"Institute of Medical Microbiology and Virology, Universit\u00e4tsmedizin G\u00f6ttingen","place":["G\u00f6ttingen, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"K\u00f6ck","sequence":"additional","affiliation":[{"name":"Hygiene and Environmental Medicine, Universit\u00e4tsmedizin Essen","place":["Essen, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frieder","family":"Schaumburg","sequence":"additional","affiliation":[{"name":"Institute of Medical Microbiology, University Hospital M\u00fcnster","place":["M\u00fcnster, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-1097(88)90228-5"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02771848"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.6.2356-2357.2001"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.9.3420-3421.2001"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-002-0747-8"},{"key":"e_1_3_4_7_2","first-page":"1073","article-title":"Isolation of coryneform bacteria from blood cultures of patients at a University Hospital in Saudi Arabia","volume":"25","author":"Babay HA","year":"2004","unstructured":"Babay HA, Kambal AM. 2004. Isolation of coryneform bacteria from blood cultures of patients at a University Hospital in Saudi Arabia. Saudi Med J 25:1073\u20131079.","journal-title":"Saudi Med J"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/2052-2975.31"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ram.2016.09.003"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14082"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2020.115118"},{"key":"e_1_3_4_12_2","unstructured":"EUCAST. 2023. The European Committee on antimicrobial susceptibility testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 13.1 2023. Available from: https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_13.1_Breakpoint_Tables.pdf"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2022.02.024"},{"key":"e_1_3_4_14_2","volume-title":"Clinical and laboratory standards institute (CLSI) M39: analysis and presentation of cumulative antimicrobial susceptibility test data","author":"CLSI","year":"2022","unstructured":"CLSI. 2022. Clinical and laboratory standards institute (CLSI) M39: analysis and presentation of cumulative antimicrobial susceptibility test data. 5th edition","edition":"5"},{"key":"e_1_3_4_15_2","unstructured":"GenBank Database National Library of Medicine. 2023. Available from: https:\/\/www.ncbi.nlm.nih.gov\/genbank\/. Retrieved 18 Oct 2023."},{"key":"e_1_3_4_16_2","unstructured":"Standardization IOf. 2019. ISO 20776-1:2019 Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices \u2014 Part 1: Broth micro-dilution reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases"},{"key":"e_1_3_4_17_2","unstructured":"EUCAST. 2022. Broth microdilution - EUCAST reading guide v 4.0. Available from: https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Disk_test_documents\/2022_manuals\/Reading_guide_BMD_v_4.0_2022.pdf. Retrieved 16 Oct 2023."},{"key":"e_1_3_4_18_2","unstructured":"EUCAST. 2023. The European Committee on Antimicrobial Susceptibility Testing.Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST. Available from: https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/QC\/v_13.2_EUCAST_QC_tables_routine_and_extended_QC.pdf"},{"key":"e_1_3_4_19_2","unstructured":"EUCAST. Establishing disk diffusion zone diameter breakpoints. Available from: https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Disk_criteria\/EUCAST_zdd_breakpoints_C.pdf"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s100960100503"},{"key":"e_1_3_4_21_2","unstructured":"EUCAST. 2021. Harmonisation of breakpoints for existing antimicrobia agents EUCAST SOP 2.4. Available from: https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/EUCAST_SOPs\/2021\/EUCAST_SOP_2.4_Setting_breakpoints_existing_agents_20211202.pdflast"},{"key":"e_1_3_4_22_2","unstructured":"EUCAST. 2021. Standard operating procedure MIC distributions and the setting of epidemiological cut-off (ECOFF) values EUCAST SOP 10.2 2 December 2021. Available from: https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/EUCAST_SOPs\/2021\/EUCAST_SOP_10.2_MIC_distributions_and_epidemiological_cut-off_value__ECOFF__setting_20211202.pdf"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chemphyslip.2016.02.002"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.11.020"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.4103\/ijmm.IJMM_20_92"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2019.03.017"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.anaerobe.2020.102217"},{"key":"e_1_3_4_28_2","unstructured":"EUCAST. 2022. Standard operating procedure procedure for establishing zone diameter breakpoints and quality control citeria for new antimicrobial agents EUCAST SOP 9.3. Available from: https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/EUCAST_SOPs\/2022\/EUCAST_SOP_9.2_Disk_diffusion_breakpoints_and_QC_ranges_final_20200721.pdf"}],"container-title":["Microbiology Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.01827-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.01827-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T14:05:25Z","timestamp":1736258725000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/spectrum.01827-24"}},"subtitle":[],"editor":[{"given":"Melissa R.","family":"Gitman","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,1,7]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,7]]}},"alternative-id":["10.1128\/spectrum.01827-24"],"URL":"https:\/\/doi.org\/10.1128\/spectrum.01827-24","relation":{},"ISSN":["2165-0497"],"issn-type":[{"type":"electronic","value":"2165-0497"}],"subject":[],"published":{"date-parts":[[2025,1,7]]},"assertion":[{"value":"2024-07-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01827-24"}}